

CDC-Funded HIV Testing in the United States, Puerto Rico, and U.S. Virgin Islands

2020 ANNUAL HIV TESTING REPORT

OVERVIEW

The Centers for Disease Control and Prevention (CDC) receives, analyzes, and disseminates data on CDC-funded HIV testing and prevention activities reported through the National HIV Prevention Program Monitoring and Evaluation (NHM&E) data reporting system, EvaluationWeb®. These data are used to assess the impact of CDC-funded HIV testing efforts, inform programmatic activities, and document the progress of programs toward local, state, and national HIV prevention goals.

This report describes the demographics of persons tested, persons with newly diagnosed HIV infection, and persons linked to HIV medical care in the United States, Puerto Rico, and U.S. Virgin Islands in 2020. Data presented in this report include HIV test-level data reported to CDC through EvaluationWeb® as of September 15, 2021 from 60 state and local health departments (HDs) and 100 community-based organizations (CBOs). It is important to note that many CDC-funded jurisdictions experienced interruptions in the provision and/or reporting of HIV testing and related services in 2020 due to the COVID-19 pandemic.



CDC-funded HIV testing by setting & site type*

A total of 1,338,665 CDC-funded HIV tests were conducted in 2020. Most tests were conducted in health care settings (75%) such as Sexually Transmitted Disease (STD) Clinics and Community Health Centers. The tables below show the number of tests conducted and the percentage of tests resulting in new diagnoses (newly diagnosed % positivity) by site type.

	TESTS (% POSITIVITY)		TESTS (% POSITIVITY)
Health care setting	1,005,553 (0.4%)	Non-health care setting	319,799 (0.8%)
STD Clinics	325,093 (0.5%)	HIV Testing Sites	158,692 (1.0%)
Community Health Centers	272,864 (0.3%)	Community Settings ^b	77,504 (0.6%)
Emergency Departments	162,491 (0.3%)	Correctional Facilities, Non-health care	13,216 (0.3%)
Correctional Clinics	59,487 (0.2%)	Other ^c	70,387 (0.7%)
Other ^a	185,618 (0.4%)		

* Not shown: 11,810 tests were conducted in mobile settings, 587 self-tests were reported, and 916 tests were missing information on site type.

^a Health care sites where medical services are provided other than those specified including primary care clinics, substance abuse treatment facilities, pharmacies, dental clinics, TB clinics, and inpatient hospitals.


^b Includes schools, churches, shelters, commercial facilities, bars/clubs, public areas, individual residences, and other community settings.

^c Non-health care sites where prevention services are conducted other than those specified including health department field visits and syringe exchange programs.


Newly diagnosed HIV positivity by age, gender, race/ethnicity and population group

Among the 1,338,665 CDC-funded HIV tests conducted, 6,458 (0.5%) resulted in new HIV diagnoses. The figures below show newly diagnosed positivity (i.e., percentage of persons with newly diagnosed HIV infection among all CDC-funded tests conducted) by demographic characteristics and population groups. Additional information, including number of tests conducted by category, can be found in Appendix Table 4.


AGE ^a




GENDER ^b



RACE & ETHNICITY ^c



POPULATION GROUP in non-health care settings ^d



^a "< 13 years" category is not shown.

^b "Transgender" category includes response options "Transgender Male to Female", "Transgender Female to Male", and "Transgender Unspecified". "Another gender" category is not shown.

^c "More than one race" category is not shown.

^d Restricted to non-health care settings because data on population groups are required for all CDC-funded tests performed in non-health care settings but only required for HIV-positive tests in health care settings. Categories are mutually exclusive and based on behaviors in past 12 months under the old NHM&E reporting requirements and in past 5 years under the new NHM&E reporting requirements. For more information, see Technical Notes. "MSM" refers to gay, bisexual, and other men who have sex with men. "PWID" refers to persons who inject drugs.

CDC-funded HIV testing in 60 jurisdictions

Among 6,458 persons with newly diagnosed HIV infection, 76% were linked to HIV medical care within 30 days of their positive test and 77% were interviewed for partner services. The reported percentages* varied by jurisdiction, as shown in Table 1 below.

Table 1. CDC-funded HIV testing and outcomes among persons with newly diagnosed HIV infection in the United States, Puerto Rico, and U.S. Virgin Islands, 2020

Jurisdictions	CDC-funded HIV tests			
	Number of HIV tests conducted in 2020	Number (%) of persons with newly diagnosed HIV	Percentage of persons with newly diagnosed HIV linked to HIV medical care within 30 days*	Percentage of persons with newly diagnosed HIV interviewed for partner services*
Alabama	47,994	284 (0.6%)	43%	75%
Alaska	554	0 (0.0%)	n/a	n/a
Arizona	39,720	174 (0.4%)	79%	94%
Arkansas	1,442	14 (1.0%)	91%	85%
California				
Los Angeles	26,306	216 (0.8%)	68%	52%
San Francisco	12,630	48 (0.4%)	91%	71%
California (excludes Los Angeles and San Francisco)	18,680	174 (0.9%)	85%	53%
Colorado	1,668	8 (0.5%)	63%	63%
Connecticut	45,282	70 (0.2%)	84%	90%
Delaware	5,052	18 (0.4%)	89%	78%
District of Columbia	12,149	94 (0.8%)	85%	35%
Florida	128,307	1,101 (0.9%)	67%	90%
Georgia	94,524	596 (0.6%)	78%	73%
Hawaii	1,305	3 (0.2%)	100%	100%
Idaho	5,286	5 (0.1%)	80%	40%
Illinois				
Chicago	5,801	51 (0.9%)	82%	82%
Illinois (excludes Chicago)	15,625	22 (0.1%)	91%	95%
Indiana	11,916	17 (0.1%)	36%	38%
Iowa	5,993	16 (0.3%)	87%	100%
Kansas	12,688	38 (0.3%)	66%	89%
Kentucky	10,890	26 (0.2%)	69%	96%
Louisiana**	80,883	215 (0.3%)	86%	100%
Maine	893	0 (0.0%)	n/a	n/a
Maryland				
Baltimore	23,713	68 (0.3%)	85%	73%
Maryland (excludes Baltimore)	15,433	28 (0.2%)	90%	57%
Massachusetts	28,542	93 (0.3%)	82%	66%
Michigan	21,458	90 (0.4%)	79%	79%
Minnesota	2,190	4 (0.2%)	25%	100%
Mississippi	32,638	151 (0.5%)	60%	91%
Missouri	34,035	66 (0.2%)	47%	95%
Montana	1,208	0 (0.0%)	n/a	n/a
Nebraska	5,093	8 (0.2%)	100%	100%
Nevada	13,680	79 (0.6%)	85%	91%

CDC-funded HIV testing in 60 jurisdictions (continued)

Table 1. CDC-funded HIV testing and outcomes among persons with newly diagnosed HIV infection in the United States, Puerto Rico, and U.S. Virgin Islands, 2020 (continued)

Jurisdictions	CDC-funded HIV tests			
	Number of HIV tests conducted in 2020	Number (%) of persons newly diagnosed with HIV	Percentage of persons with newly diagnosed HIV linked to HIV medical care within 30 days*	Percentage of persons with newly diagnosed HIV interviewed for partner services*
New Hampshire	466	4 (0.9%)	100%	100%
New Jersey	26,895	119 (0.4%)	89%	74%
New Mexico	5,275	25 (0.5%)	88%	92%
New York				
New York City	34,618	231 (0.7%)	85%	61%
New York (excludes New York City)	9,864	88 (0.9%)	89%	89%
North Carolina	18,765	47 (0.3%)	70%	87%
North Dakota	2,973	3 (0.1%)	33%	67%
Ohio	7,205	134 (1.9%)	88%	86%
Oklahoma	3,143	24 (0.8%)	80%	100%
Oregon	5,578	25 (0.4%)	84%	92%
Pennsylvania				
Philadelphia	25,978	104 (0.4%)	91%	73%
Pennsylvania (excludes Philadelphia)	45,631	119 (0.3%)	85%	86%
Rhode Island	1,196	2 (0.2%)	100%	100%
South Carolina	36,018	185 (0.5%)	79%	71%
South Dakota	411	0 (0.0%)	n/a	n/a
Tennessee	61,427	354 (0.6%)	66%	74%
Texas				
Houston	54,899	265 (0.5%)	86%	83%
Texas (excludes Houston)	177,725	666 (0.4%)	76%	59%
Utah	995	2 (0.2%)	100%	100%
Vermont	42	2 (4.8%)	100%	100%
Virginia	26,920	120 (0.4%)	85%	72%
Washington	7,632	49 (0.6%)	92%	52%
West Virginia	1,745	3 (0.2%)	100%	100%
Wisconsin	6,800	24 (0.4%)	92%	88%
Wyoming	2,408	1 (0.0%)	0%	100%
Puerto Rico	9,392	82 (0.9%)	85%	94%
U.S. Virgin Islands	1,086	3 (0.3%)	100%	33%
Total	1,338,665	6,458 (0.5%)	76%	77%

n/a= not applicable

* Reported percentages exclude tests without data to calculate the outcome (i.e., invalid, missing, or "Don't Know").

** Experienced reporting challenges as a result of Hurricane Ida.

CDC-Funded HIV Testing in the United States, Puerto Rico, and U.S. Virgin Islands

2020 ANNUAL HIV TESTING REPORT

TECHNICAL NOTES

Data presented in this report include HIV test-level data from 60 state and local health departments (HDs) and 100 community-based organizations (CBOs) directly funded by CDC through 5 funding opportunities ([PS15-1502](#), [PS15-1509](#), [PS17-1704](#), [PS18-1802](#), and [PS20-2010](#)) and reported to CDC through EvaluationWeb® as of September 15, 2021. HDs funded through PS18-1802 and PS20-2010 and CBOs funded through PS17-1704 transitioned to new NHM&E data reporting requirements (i.e., required set of variables and program indicators) in 2018-2019. CBOs directly funded through PS15-1502 did not transition to new reporting requirements. Test-level data reported under the old and new requirements were analyzed separately and resulting counts were combined in the tables and figures displayed.

DEFINITIONS AND INTERPRETING THIS REPORT

- An HIV test is defined as a sequence of one or more HIV tests conducted to determine a person's HIV status.
- Total tests include only tests with negative or positive results; tests with discordant or inconclusive results are excluded.
- NHM&E data are collected at the test-level; therefore, data included in this report represent test records rather than individuals. Clients tested multiple times may be included in the data.
- A person with newly diagnosed HIV is defined as a person who tests positive on the current test (includes persons with unconfirmed preliminary positive rapid tests and persons with confirmed positive tests) and has no indication of a previous positive test.
- The reported percentage of persons linked to HIV medical care within 30 days is calculated by excluding tests with missing or unknown outcome data from the denominator, which likely overestimates actual linkage. Similarly, the reported percentage of persons interviewed for partner services is calculated by excluding tests with missing or unknown outcome data from the denominator, which likely overestimates the actual percentage interviewed.
- Procedures for data collection and verification vary among jurisdictions. For example, some jurisdictions accept a client's self-report as adequate evidence that the client is newly diagnosed or has been linked to HIV medical care; whereas others require a cross-check with the surveillance system to rule out prior diagnosis or to verify linkage to care.
- Jurisdictions vary considerably in resources available for HIV prevention and in the contexts in which they operate, which can affect program capacity. For example, some jurisdictions may receive state and local funds in addition to federal funds, whereas others may not. Examples of contextual issues that may affect program capacity include HIV prevalence, geography, political environment, laws and regulations, program infrastructure, surveillance system capacity, and accessibility to surveillance data to help guide program activities.
- Because the population accessing HIV testing services at publicly funded sites is not necessarily representative of all persons who are tested for HIV in the United States, these findings should not be applied to the general population.

ACKNOWLEDGEMENTS

Publication of this report would not have been possible without the hard work and dedication of state and local health departments and community-based organizations that collected and submitted the HIV test-level data. This report was prepared by Nicoline Collins, Guoshen Wang, Songli Xu, and Carolyn Wright of the Translation and Evaluation Branch in the Division of HIV Prevention. We also acknowledge the contributions of Lisa Belcher, Janet Heitgerd, and Yuko Mizuno of the Translation and Evaluation Branch; the Office of Informatics and Data Management; and the Program Development and Implementation Branch for their contribution toward monitoring and strengthening HIV prevention efforts in state and local health departments and community-based organizations.

Suggested citation: Centers for Disease Control and Prevention. *CDC-Funded HIV Testing in the United States, Puerto Rico, and the U.S. Virgin Islands, 2020*. <http://www.cdc.gov/hiv/library/reports/index.html>. Published January 2022. Accessed [Date].

CDC-Funded HIV Testing in the United States, Puerto Rico, and U.S. Virgin Islands

2020 ANNUAL HIV TESTING REPORT

APPENDIX: DETAILED TABLES

Table 1. Number of CDC-funded HIV tests and HIV positivity, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2020

Table 2. Number of CDC-funded HIV tests and newly diagnosed HIV positivity in health care and non-health care settings, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2020

Table 3. CDC-funded HIV testing and linkage to HIV medical care among persons with newly diagnosed HIV infection, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2020

Table 4. CDC-funded HIV testing and linkage to HIV medical care among persons with newly diagnosed HIV infection by demographic characteristics, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2020

Table 5. CDC-funded HIV testing and interview for partner services among persons with newly diagnosed HIV infection, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2020

Table 6. CDC-funded HIV testing and linkage to HIV medical care among persons with previously diagnosed HIV infection not in HIV medical care, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2020

For more information, contact:

Division of HIV Prevention
National Center for HIV, Viral Hepatitis, STD, and TB Prevention
U.S. Centers for Disease Control and Prevention
1600 Clifton Road NE, Atlanta, GA 30329
Phone: 1-800-CDC-INFO
Web address: <http://www.cdc.gov/HIV>

National HIV Prevention Program Monitoring and Evaluation Service Center
Phone: 1-855-374-7310, Email: NHMEservice@cdc.gov

Table 1. Number of CDC-funded HIV tests and HIV positivity, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2020

CDC-funded jurisdiction	HIV-positive tests ^b								
	HIV tests ^a	Newly diagnosed HIV-positive tests ^c		Previously diagnosed HIV-positive tests ^d		Unable to determine prior HIV status ^e		Total	
	No.	No.	(%)	No.	(%)	No.	(%)	No.	(%)
Alabama	47,994	284	(0.6)	341	(0.7)	82	(0.2)	707	(1.5)
Alaska	554	0	(0.0)	2	(0.4)	0	(0.0)	2	(0.4)
Arizona	39,720	174	(0.4)	69	(0.2)	35	(0.1)	278	(0.7)
Arkansas	1,442	14	(1.0)	47	(3.3)	112	(7.8)	173	(12.0)
California									
Los Angeles	26,306	216	(0.8)	238	(0.9)	4	(0.0)	458	(1.7)
San Francisco	12,630	48	(0.4)	83	(0.7)	0	(0.0)	131	(1.0)
California (excludes Los Angeles and San Francisco)	18,680	174	(0.9)	110	(0.6)	16	(0.1)	300	(1.6)
Colorado	1,668	8	(0.5)	5	(0.3)	0	(0.0)	13	(0.8)
Connecticut	45,282	70	(0.2)	24	(0.1)	3	(0.0)	97	(0.2)
Delaware	5,052	18	(0.4)	10	(0.2)	0	(0.0)	28	(0.6)
District of Columbia	12,149	94	(0.8)	79	(0.7)	2	(0.0)	175	(1.4)
Florida	128,307	1,101	(0.9)	838	(0.7)	116	(0.1)	2,055	(1.6)
Georgia	94,524	596	(0.6)	247	(0.3)	25	(0.0)	868	(0.9)
Hawaii	1,305	3	(0.2)	1	(0.1)	2	(0.2)	6	(0.5)
Idaho	5,286	5	(0.1)	0	(0.0)	0	(0.0)	5	(0.1)
Illinois									
Chicago	5,801	51	(0.9)	63	(1.1)	1	(0.0)	115	(2.0)
Illinois (excludes Chicago)	15,625	22	(0.1)	21	(0.1)	4	(0.0)	47	(0.3)
Indiana	11,916	17	(0.1)	2	(0.0)	35	(0.3)	54	(0.5)
Iowa	5,993	16	(0.3)	1	(0.0)	6	(0.1)	23	(0.4)
Kansas	12,688	38	(0.3)	2	(0.0)	7	(0.1)	47	(0.4)
Kentucky	10,890	26	(0.2)	18	(0.2)	17	(0.2)	61	(0.6)
Louisiana ^f	80,883	215	(0.3)	653	(0.8)	100	(0.1)	968	(1.2)
Maine	893	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Maryland									
Baltimore	23,713	68	(0.3)	174	(0.7)	1	(0.0)	243	(1.0)
Maryland (excludes Baltimore)	15,433	28	(0.2)	36	(0.2)	0	(0.0)	64	(0.4)
Massachusetts	28,542	93	(0.3)	333	(1.2)	0	(0.0)	426	(1.5)
Michigan	21,458	90	(0.4)	61	(0.3)	4	(0.0)	155	(0.7)
Minnesota	2,190	4	(0.2)	11	(0.5)	2	(0.1)	17	(0.8)

		HIV-positive tests ^b							
CDC-funded jurisdiction	HIV tests ^a	Newly diagnosed HIV-positive tests ^c		Previously diagnosed HIV-positive tests ^d		Unable to determine prior HIV status ^e		Total	
	No.	No.	(%)	No.	(%)	No.	(%)	No.	(%)
Mississippi	32,638	151	(0.5)	48	(0.1)	1	(0.0)	200	(0.6)
Missouri	34,035	66	(0.2)	87	(0.3)	22	(0.1)	175	(0.5)
Montana	1,208	0	(0.0)	0	(0.0)	3	(0.2)	3	(0.2)
Nebraska	5,093	8	(0.2)	6	(0.1)	0	(0.0)	14	(0.3)
Nevada	13,680	79	(0.6)	71	(0.5)	8	(0.1)	158	(1.2)
New Hampshire	466	4	(0.9)	0	(0.0)	0	(0.0)	4	(0.9)
New Jersey	26,895	119	(0.4)	143	(0.5)	68	(0.3)	330	(1.2)
New Mexico	5,275	25	(0.5)	4	(0.1)	2	(0.0)	31	(0.6)
New York									
New York City	34,618	231	(0.7)	213	(0.6)	15	(0.0)	459	(1.3)
New York (excludes New York City)	9,864	88	(0.9)	161	(1.6)	16	(0.2)	265	(2.7)
North Carolina	18,765	47	(0.3)	104	(0.6)	0	(0.0)	151	(0.8)
North Dakota	2,973	3	(0.1)	0	(0.0)	0	(0.0)	3	(0.1)
Ohio	7,205	134	(1.9)	36	(0.5)	0	(0.0)	170	(2.4)
Oklahoma	3,143	24	(0.8)	4	(0.1)	89	(2.8)	117	(3.7)
Oregon	5,578	25	(0.4)	9	(0.2)	0	(0.0)	34	(0.6)
Pennsylvania									
Pennsylvania (excludes Philadelphia)	45,631	119	(0.3)	272	(0.6)	21	(0.0)	412	(0.9)
Philadelphia	25,978	104	(0.4)	152	(0.6)	57	(0.2)	313	(1.2)
Rhode Island	1,196	2	(0.2)	0	(0.0)	2	(0.2)	4	(0.3)
South Carolina	36,018	185	(0.5)	62	(0.2)	42	(0.1)	289	(0.8)
South Dakota	411	0	(0.0)	0	(0.0)	3	(0.7)	3	(0.7)
Tennessee	61,427	354	(0.6)	84	(0.1)	189	(0.3)	627	(1.0)
Texas									
Houston	54,899	265	(0.5)	461	(0.8)	0	(0.0)	726	(1.3)
Texas (excludes Houston)	177,725	666	(0.4)	899	(0.5)	1	(0.0)	1,566	(0.9)
Utah	995	2	(0.2)	1	(0.1)	0	(0.0)	3	(0.3)
Vermont	42	2	(4.8)	0	(0.0)	0	(0.0)	2	(4.8)
Virginia	26,920	120	(0.4)	82	(0.3)	0	(0.0)	202	(0.8)
Washington	7,632	49	(0.6)	6	(0.1)	2	(0.0)	57	(0.7)
West Virginia	1,745	3	(0.2)	0	(0.0)	16	(0.9)	19	(1.1)
Wisconsin	6,800	24	(0.4)	11	(0.2)	2	(0.0)	37	(0.5)

CDC-funded jurisdiction	HIV-positive tests ^b								
	HIV tests ^a	Newly diagnosed HIV-positive tests ^c		Previously diagnosed HIV-positive tests ^d		Unable to determine prior HIV status ^e		Total	
	No.	No.	(%)	No.	(%)	No.	(%)	No.	(%)
Wyoming	2,408	1	(0.0)	0	(0.0)	6	(0.2)	7	(0.3)
Puerto Rico	9,392	82	(0.9)	63	(0.7)	1	(0.0)	146	(1.6)
U.S. Virgin Islands	1,086	3	(0.3)	6	(0.6)	0	(0.0)	9	(0.8)
Total	1,338,665	6,458	(0.5)	6,455	(0.5)	1,140	(0.1)	14,053	(1.0)

Data Source: Centers for Disease Control and Prevention National HIV Prevention Program Monitoring and Evaluation (NHM&E) data reported through EvaluationWeb[®] as of September 15, 2021.

^a Includes only tests with negative or positive results; tests with discordant or inconclusive results are excluded.

^b Includes unconfirmed preliminary positive rapid tests and confirmed positive tests.

^c A newly diagnosed HIV-positive test refers to a person who has a current HIV-positive test result (includes unconfirmed preliminary positive rapid tests and confirmed positive tests) and no indication of a previous HIV-positive test.

^d A previously diagnosed HIV-positive test is a test on a client who was previously reported to the HIV surveillance system or who reports a previous positive HIV test or evidence of a previous positive test is found on review of other data sources.

^e A positive test that was missing information on prior HIV status or was reported as unable to determine prior HIV status (i.e., the HIV surveillance system was not checked, no other data sources were reviewed and there is no information from the client about previous HIV test results).

^f Experienced reporting challenges because of Hurricane Ida.

Table 2. Number of CDC-funded HIV tests and newly diagnosed HIV positivity in health care and non-health care settings, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2020

CDC-funded jurisdiction	Health care settings				Non-health care settings			
	HIV tests ^a		Newly diagnosed HIV-positive tests ^b		HIV tests ^a		Newly diagnosed HIV-positive tests ^b	
	No.	(%)	No.	(%)	No.	(%)	No.	(%)
Alabama	305	(0.6)	6	(2.0)	47,689	(99.4)	278	(0.6)
Alaska	161	(29.1)	0	(0.0)	386	(69.7)	0	(0.0)
Arizona	34,878	(87.8)	164	(0.5)	4,228	(10.6)	9	(0.2)
Arkansas	421	(29.2)	0	(0.0)	983	(68.2)	14	(1.4)
California								
Los Angeles	14,143	(53.8)	101	(0.7)	10,039	(38.2)	99	(1.0)
San Francisco	12,323	(97.6)	48	(0.4)	307	(2.4)	0	(0.0)
California (excludes Los Angeles and San Francisco)	11,700	(62.6)	116	(1.0)	4,317	(23.1)	38	(0.9)
Colorado	0	(0.0)	0	(0.0)	1,660	(99.5)	8	(0.5)
Connecticut	44,212	(97.6)	64	(0.1)	1,070	(2.4)	6	(0.6)
Delaware	3,353	(66.4)	8	(0.2)	1,680	(33.3)	9	(0.5)
District of Columbia	3,712	(30.6)	58	(1.6)	8,378	(69.0)	34	(0.4)
Florida	77,418	(60.3)	545	(0.7)	48,172	(37.5)	542	(1.1)
Georgia	65,318	(69.1)	245	(0.4)	28,356	(30.0)	349	(1.2)
Hawaii	379	(29.0)	1	(0.3)	926	(71.0)	2	(0.2)
Idaho	4,912	(92.9)	2	(0.0)	372	(7.0)	3	(0.8)
Illinois								
Chicago	2,683	(46.3)	27	(1.0)	3,080	(53.1)	24	(0.8)
Illinois (excludes Chicago)	9,016	(57.7)	11	(0.1)	6,609	(42.3)	11	(0.2)
Indiana	6,066	(50.9)	3	(0.0)	5,850	(49.1)	14	(0.2)
Iowa	4,961	(82.8)	14	(0.3)	1,032	(17.2)	2	(0.2)
Kansas	10,368	(81.7)	22	(0.2)	2,320	(18.3)	16	(0.7)
Kentucky	8,853	(81.3)	15	(0.2)	2,037	(18.7)	11	(0.5)
Louisiana ^c	68,994	(85.3)	151	(0.2)	11,797	(14.6)	64	(0.5)
Maine	670	(75.0)	0	(0.0)	187	(20.9)	0	(0.0)
Maryland								
Baltimore	22,287	(94.0)	64	(0.3)	1,426	(6.0)	4	(0.3)
Maryland (excludes Baltimore)	13,989	(90.6)	28	(0.2)	1,438	(9.3)	0	(0.0)
Massachusetts	26,689	(93.5)	85	(0.3)	1,853	(6.5)	8	(0.4)
Michigan	19,558	(91.1)	78	(0.4)	1,868	(8.7)	12	(0.6)

CDC-funded jurisdiction	Health care settings				Non-health care settings			
	HIV tests ^a		Newly diagnosed HIV-positive tests ^b		HIV tests ^a		Newly diagnosed HIV-positive tests ^b	
	No.	(%)	No.	(%)	No.	(%)	No.	(%)
Minnesota	245	(11.2)	2	(0.8)	1,945	(88.8)	2	(0.1)
Mississippi	31,150	(95.4)	141	(0.5)	1,399	(4.3)	9	(0.6)
Missouri	30,309	(89.1)	54	(0.2)	3,726	(10.9)	12	(0.3)
Montana	560	(46.4)	0	(0.0)	643	(53.2)	0	(0.0)
Nebraska	3,908	(76.7)	6	(0.2)	1,185	(23.3)	2	(0.2)
Nevada	5,972	(43.7)	27	(0.5)	7,708	(56.3)	52	(0.7)
New Hampshire	287	(61.6)	3	(1.0)	179	(38.4)	1	(0.6)
New Jersey	17,344	(64.5)	71	(0.4)	9,551	(35.5)	48	(0.5)
New Mexico	4,241	(80.4)	20	(0.5)	1,034	(19.6)	5	(0.5)
New York								
New York City	31,553	(91.1)	182	(0.6)	2,988	(8.6)	48	(1.6)
New York (excludes New York City)	3,522	(35.7)	58	(1.6)	5,924	(60.1)	27	(0.5)
North Carolina	2,559	(13.6)	8	(0.3)	16,130	(86.0)	39	(0.2)
North Dakota	250	(8.4)	0	(0.0)	2,723	(91.6)	3	(0.1)
Ohio	4,168	(57.8)	91	(2.2)	3,037	(42.2)	43	(1.4)
Oklahoma	179	(5.7)	0	(0.0)	2,964	(94.3)	24	(0.8)
Oregon	4,745	(85.1)	24	(0.5)	780	(14.0)	1	(0.1)
Pennsylvania								
Pennsylvania (excludes Philadelphia)	42,128	(92.3)	104	(0.2)	3,503	(7.7)	15	(0.4)
Philadelphia	22,926	(88.3)	87	(0.4)	2,543	(9.8)	14	(0.6)
Rhode Island	10	(0.8)	0	(0.0)	1,100	(92.0)	0	(0.0)
South Carolina	29,174	(81.0)	89	(0.3)	6,820	(18.9)	96	(1.4)
South Dakota	183	(44.5)	0	(0.0)	228	(55.5)	0	(0.0)
Tennessee	56,563	(92.1)	292	(0.5)	4,620	(7.5)	62	(1.3)
Texas								
Houston	50,103	(91.3)	138	(0.3)	4,796	(8.7)	127	(2.6)
Texas (excludes Houston)	155,951	(87.7)	408	(0.3)	19,698	(11.1)	233	(1.2)
Utah	992	(99.7)	2	(0.2)	3	(0.3)	0	(0.0)
Vermont	0	(0.0)	0	(0.0)	42	(100.0)	2	(4.8)
Virginia	20,237	(75.2)	72	(0.4)	6,333	(23.5)	47	(0.7)
Washington	4,731	(62.0)	25	(0.5)	2,901	(38.0)	24	(0.8)
West Virginia	1,553	(89.0)	3	(0.2)	192	(11.0)	0	(0.0)

CDC-funded jurisdiction	Health care settings				Non-health care settings			
	HIV tests ^a		Newly diagnosed HIV-positive tests ^b		HIV tests ^a		Newly diagnosed HIV-positive tests ^b	
	No.	(%)	No.	(%)	No.	(%)	No.	(%)
Wisconsin	3,628	(53.4)	16	(0.4)	3,172	(46.6)	8	(0.3)
Wyoming	2,400	(99.7)	1	(0.0)	8	(0.3)	0	(0.0)
Puerto Rico	5,913	(63.0)	74	(1.3)	3,478	(37.0)	8	(0.2)
U.S. Virgin Islands	700	(64.5)	3	(0.4)	386	(35.5)	0	(0.0)
Total	1,005,553	(75.1)	3,857	(0.4)	319,799	(23.9)	2,509	(0.8)

Data Source: Centers for Disease Control and Prevention National HIV Prevention Program Monitoring and Evaluation (NHM&E) data reported through EvaluationWeb[®] as of September 15, 2021.

^a Includes only tests with negative or positive results; tests with discordant or inconclusive results are excluded.

^b A newly diagnosed HIV-positive test refers to a person who has a current HIV-positive test result (includes unconfirmed preliminary positive rapid tests and confirmed positive tests) and no indication of a previous HIV-positive test.

^c Experienced reporting challenges because of Hurricane Ida.

Table 3. CDC-funded HIV testing and linkage to HIV medical care among persons with newly diagnosed HIV infection, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2020

CDC-funded jurisdiction	HIV tests			Linkage to HIV Medical Care in 30 days ^c					
	All HIV tests ^a	Newly diagnosed HIV-positive tests ^b	Newly diagnosed HIV positivity (%)	Linked	Not linked	Missing/invalid	Missing/invalid (%)	Denominator for reported percentage ^d	Reported percentage ^e (%)
Alabama	47,994	284	(0.6)	114	153	17	(6.0)	267	(42.7)
Alaska	554	0	----	----	----	----	----	----	----
Arizona	39,720	174	(0.4)	137	37	0	(0.0)	174	(78.7)
Arkansas	1,442	14	(1.0)	10	1	3	(21.4)	11	(90.9)
California									
Los Angeles	26,306	216	(0.8)	133	62	21	(9.7)	195	(68.2)
San Francisco	12,630	48	(0.4)	20	2	26	(54.2)	22	(90.9)
California (excludes Los Angeles and San Francisco)	18,680	174	(0.9)	141	24	9	(5.2)	165	(85.5)
Colorado	1,668	8	(0.5)	5	3	0	(0.0)	8	(62.5)
Connecticut	45,282	70	(0.2)	59	11	0	(0.0)	70	(84.3)
Delaware	5,052	18	(0.4)	16	2	0	(0.0)	18	(88.9)
District of Columbia	12,149	94	(0.8)	75	13	6	(6.4)	88	(85.2)
Florida	128,307	1,101	(0.9)	482	240	379	(34.4)	722	(66.8)
Georgia	94,524	596	(0.6)	417	115	64	(10.7)	532	(78.4)
Hawaii	1,305	3	(0.2)	3	0	0	(0.0)	3	(100.0)
Idaho	5,286	5	(0.1)	4	1	0	(0.0)	5	(80.0)
Illinois									
Chicago	5,801	51	(0.9)	28	6	17	(33.3)	34	(82.4)
Illinois (excludes Chicago)	15,625	22	(0.1)	20	2	0	(0.0)	22	(90.9)
Indiana	11,916	17	(0.1)	4	7	6	(35.3)	11	(36.4)
Iowa	5,993	16	(0.3)	13	2	1	(6.3)	15	(86.7)
Kansas	12,688	38	(0.3)	25	13	0	(0.0)	38	(65.8)
Kentucky	10,890	26	(0.2)	9	4	13	(50.0)	13	(69.2)
Louisiana ^f	80,883	215	(0.3)	158	26	31	(14.4)	184	(85.9)
Maine	893	0	----	----	----	----	----	----	----
Maryland									
Baltimore	23,713	68	(0.3)	57	10	1	(1.5)	67	(85.1)
Maryland (excludes Baltimore)	15,433	28	(0.2)	18	2	8	(28.6)	20	(90.0)
Massachusetts	28,542	93	(0.3)	75	16	2	(2.2)	91	(82.4)
Michigan	21,458	90	(0.4)	66	18	6	(6.7)	84	(78.6)

CDC-funded jurisdiction	HIV tests			Linkage to HIV Medical Care in 30 days ^c					
	All HIV tests ^a	Newly diagnosed HIV-positive tests ^b	Newly diagnosed HIV positivity (%)	Linked	Not linked	Missing/invalid	Missing/invalid (%)	Denominator for reported percentage ^d	Reported percentage ^e (%)
Minnesota	2,190	4	(0.2)	1	3	0	(0.0)	4	(25.0)
Mississippi	32,638	151	(0.5)	88	58	5	(3.3)	146	(60.3)
Missouri	34,035	66	(0.2)	20	23	23	(34.8)	43	(46.5)
Montana	1,208	0	----	----	----	----	----	----	----
Nebraska	5,093	8	(0.2)	7	0	1	(12.5)	7	(100.0)
Nevada	13,680	79	(0.6)	60	11	8	(10.1)	71	(84.5)
New Hampshire	466	4	(0.9)	4	0	0	(0.0)	4	(100.0)
New Jersey	26,895	119	(0.4)	102	13	4	(3.4)	115	(88.7)
New Mexico	5,275	25	(0.5)	21	3	1	(4.0)	24	(87.5)
New York									
New York City	34,618	231	(0.7)	181	31	19	(8.2)	212	(85.4)
New York (excludes New York City)	9,864	88	(0.9)	78	10	0	(0.0)	88	(88.6)
North Carolina	18,765	47	(0.3)	30	13	4	(8.5)	43	(69.8)
North Dakota	2,973	3	(0.1)	1	2	0	(0.0)	3	(33.3)
Ohio	7,205	134	(1.9)	115	16	3	(2.2)	131	(87.8)
Oklahoma	3,143	24	(0.8)	16	4	4	(16.7)	20	(80.0)
Oregon	5,578	25	(0.4)	21	4	0	(0.0)	25	(84.0)
Pennsylvania									
Pennsylvania (excludes Philadelphia)	45,631	119	(0.3)	101	18	0	(0.0)	119	(84.9)
Philadelphia	25,978	104	(0.4)	92	9	3	(2.9)	101	(91.1)
Rhode Island	1,196	2	(0.2)	2	0	0	(0.0)	2	(100.0)
South Carolina	36,018	185	(0.5)	119	32	34	(18.4)	151	(78.8)
South Dakota	411	0	----	----	----	----	----	----	----
Tennessee	61,427	354	(0.6)	39	20	295	(83.3)	59	(66.1)
Texas									
Houston	54,899	265	(0.5)	148	24	93	(35.1)	172	(86.0)
Texas (excludes Houston)	177,725	666	(0.4)	468	148	50	(7.5)	616	(76.0)
Utah	995	2	(0.2)	2	0	0	(0.0)	2	(100.0)
Vermont	42	2	(4.8)	2	0	0	(0.0)	2	(100.0)
Virginia	26,920	120	(0.4)	97	17	6	(5.0)	114	(85.1)
Washington	7,632	49	(0.6)	44	4	1	(2.0)	48	(91.7)
West Virginia	1,745	3	(0.2)	2	0	1	(33.3)	2	(100.0)
Wisconsin	6,800	24	(0.4)	22	2	0	(0.0)	24	(91.7)

CDC-funded jurisdiction	HIV tests			Linkage to HIV Medical Care in 30 days ^c					
	All HIV tests ^a	Newly diagnosed HIV-positive tests ^b	Newly diagnosed HIV positivity (%)	Linked	Not linked	Missing/invalid	Missing/invalid (%)	Denominator for reported percentage ^d	Reported percentage ^e (%)
Wyoming	2,408	1	(0.0)	0	1	0	(0.0)	1	(0.0)
Puerto Rico	9,392	82	(0.9)	68	12	2	(2.4)	80	(85.0)
U.S. Virgin Islands	1,086	3	(0.3)	2	0	1	(33.3)	2	(100.0)
Total	1,338,665	6,458	(0.5)	4,042	1,248	1,168	(18.1)	5,290	(76.4)

Data Source: Centers for Disease Control and Prevention National HIV Prevention Program Monitoring and Evaluation (NHM&E) data reported through EvaluationWeb[®] as of September 15, 2021.

^a Includes only tests with negative or positive results; tests with discordant or inconclusive results are excluded.

^b A newly diagnosed HIV-positive test refers to a person who has a current HIV-positive test result (includes unconfirmed preliminary positive rapid tests and confirmed positive tests) and no indication of a previous HIV-positive test.

^c A person is considered linked to HIV medical care within 30 days if they have attended an appointment for HIV medical care within 30 days of diagnosis.

^d Number of persons with newly diagnosed HIV whose test records have valid and complete information on attendance and date of first appointment for HIV medical care within 30 days. This is the denominator used to calculate the reported percentage.

^e Reported percentage excludes tests without data to calculate the outcome (i.e., invalid, missing, or "Don't Know").

^f Experienced reporting challenges because of Hurricane Ida.

Table 4. CDC-funded HIV testing and linkage to HIV medical care among persons with newly diagnosed HIV infection by demographic characteristics, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2020

Characteristics	HIV tests				Linkage to HIV medical care in 30 days ^c					
	All tests ^a	Percent of all tests (%)	Newly diagnosed HIV-positive tests ^b	Newly diagnosed HIV positivity (%)	Linked	Not linked	Missing /invalid	Missing /invalid (%)	Denominator for reported percentage ^d	Reported percentage ^e (%)
Age at test (years)										
<13	3,088	(0.2)	10	(0.3)	4	3	3	(30.0)	7	(57.1)
13-19	76,250	(5.7)	205	(0.3)	133	30	42	(20.5)	163	(81.6)
20-29	475,101	(35.5)	2,747	(0.6)	1,809	520	418	(15.2)	2,329	(77.7)
30-39	345,867	(25.8)	1,882	(0.5)	1,180	368	334	(17.7)	1,548	(76.2)
40-49	190,034	(14.2)	846	(0.4)	502	160	184	(21.7)	662	(75.8)
50+	230,959	(17.3)	729	(0.3)	396	166	167	(22.9)	562	(70.5)
Missing/invalid	17,366	(1.3)	39	(0.2)	18	1	20	(51.3)	19	(94.7)
Gender										
Male	706,147	(52.8)	5,399	(0.8)	3,417	1,025	957	(17.7)	4,442	(76.9)
Female	618,263	(46.2)	865	(0.1)	502	183	180	(20.8)	685	(73.3)
Transgender	9,767	(0.7)	165	(1.7)	102	36	27	(16.4)	138	(73.9)
Another gender	1,461	(0.1)	11	(0.8)	9	1	1	(9.1)	10	(90.0)
Declined/not asked/unknown/missing	3,027	(0.2)	18	(0.6)	12	3	3	(16.7)	15	(80.0)
Race/Ethnicity										
American Indian or Alaska Native	7,965	(0.6)	35	(0.4)	22	9	4	(11.4)	31	(71.0)
Asian	27,210	(2.0)	105	(0.4)	65	13	27	(25.7)	78	(83.3)
Black or African American	545,865	(40.8)	3,148	(0.6)	1,888	657	603	(19.2)	2,545	(74.2)
Hispanic or Latino	308,093	(23.0)	1,718	(0.6)	1,198	256	264	(15.4)	1,454	(82.4)
Native Hawaiian or Pacific Islander	2,428	(0.2)	17	(0.7)	10	4	3	(17.6)	14	(71.4)
White	370,405	(27.7)	1,261	(0.3)	757	267	237	(18.8)	1,024	(73.9)
More than one race selected	9,615	(0.7)	54	(0.6)	34	16	4	(7.4)	50	(68.0)
Declined	19,778	(1.5)	35	(0.2)	22	7	6	(17.1)	29	(75.9)
Don't know/not asked	30,836	(2.3)	77	(0.2)	40	18	19	(24.7)	58	(69.0)
Missing/invalid	16,470	(1.2)	8	(0.0)	6	1	1	(12.5)	7	(85.7)
Population groups in non-health care facilities^f										
Men who have sex with men and who inject drugs	2,912	(0.9)	94	(3.2)	50	24	20	(21.3)	74	(67.6)
Men who have sex with men	74,370	(23.3)	1,568	(2.1)	1,063	252	253	(16.1)	1,315	(80.8)
Transgender persons who inject drugs	468	(0.1)	7	(1.5)	2	4	1	(14.3)	6	(33.3)
Transgender persons	4,158	(1.3)	83	(2.0)	50	17	16	(19.3)	67	(74.6)

Characteristics	HIV tests				Linkage to HIV medical care in 30 days ^c					
	All tests ^a	Percent of all tests (%)	Newly diagnosed HIV-positive tests ^b	Newly diagnosed HIV positivity (%)	Linked	Not linked	Missing /invalid	Missing /invalid (%)	Denominator for reported percentage ^d	Reported percentage ^e (%)
Persons who inject drugs	19,244	(6.0)	51	(0.3)	27	11	13	(25.5)	38	(71.1)
Heterosexual men	76,307	(23.9)	248	(0.3)	148	49	51	(20.6)	197	(75.1)
Heterosexual women	85,712	(26.8)	201	(0.2)	118	37	46	(22.9)	155	(76.1)
Women who have sex with women	3,137	(1.0)	2	(0.1)	1	0	1	(50.0)	1	(100.0)
Sex with transgender persons	541	(0.2)	5	(0.9)	3	2	0	(0.0)	5	(60.0)
No sexual contact or injection drug use	17,777	(5.6)	91	(0.5)	51	12	28	(30.8)	63	(81.0)
Missing/invalid	35,173	(11.0)	159	(0.5)	54	96	9	(5.7)	150	(36.0)
Region										
Northeast	219,407	(16.4)	832	(0.4)	696	108	28	(3.4)	804	(86.6)
Midwest	132,188	(9.9)	473	(0.4)	322	94	57	(12.1)	416	(77.4)
South	833,667	(62.3)	4,259	(0.5)	2,363	882	1,014	(23.8)	3,245	(72.8)
West	142,925	(10.7)	809	(0.6)	591	152	66	(8.2)	743	(79.5)
U.S. dependent areas	10,478	(0.8)	85	(0.8)	70	12	3	(3.5)	82	(85.4)
Testing site type										
Health care facilities	1,005,553	(75.1)	3,857	(0.4)	2,426	722	709	(18.4)	3,148	(77.1)
Non-health care facilities	319,799	(23.9)	2,509	(0.8)	1,567	504	438	(17.5)	2,071	(75.7)
Mobile units	11,810	(0.9)	71	(0.6)	36	21	14	(19.7)	57	(63.2)
Self-testing	587	(0.0)	4	(0.7)	3	0	1	(25.0)	3	(100.0)
Missing	916	(0.1)	17	(1.9)	10	1	6	(35.3)	11	(90.9)
Total	1,338,665	(100.0)	6,458	(0.5)	4,042	1,248	1,168	(18.1)	5,290	(76.4)

Data Source: Centers for Disease Control and Prevention National HIV Prevention Program Monitoring and Evaluation (NHM&E) data reported through EvaluationWeb® as of September 15, 2021.

^a Includes only tests with negative or positive results; tests with discordant or inconclusive results are excluded.

^b A newly diagnosed HIV-positive test refers to a person who has a current HIV-positive test result (includes unconfirmed preliminary positive rapid tests and confirmed positive tests) and no indication of a previous HIV-positive test.

^c A person is considered linked to HIV medical care within 30 days if they have attended an appointment for HIV medical care within 30 days of diagnosis.

^d Number of persons with newly diagnosed HIV whose test records have valid and complete information on attendance and date of first appointment for HIV medical care within 30 days. This is the denominator used to calculate the reported percentage.

^e Reported percentage excludes tests without data to calculate the outcome (i.e., invalid, missing, or "Don't Know").

^f Restricted to non-health care settings because data on population groups are required in non-health care settings, but only required for HIV-positive tests in health care settings. Categories are mutually exclusive and based on behaviors in past 12 months under the old NHM&E reporting requirements and in past 5 years under the new requirements.

Table 5. CDC-funded HIV testing and interview for partner services among persons with newly diagnosed HIV infection, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2020

CDC-funded jurisdiction	HIV tests			Interview for Partner Services					
	All HIV tests ^a	Newly diagnosed HIV-positive tests ^b	Newly diagnosed HIV positivity (%)	Interviewed	Not Interviewed	Missing/invalid	Missing /invalid (%)	Denominator for reported percentage ^c	Reported percentage ^d (%)
Alabama	47,994	284	(0.6)	191	65	28	(9.9)	256	(74.6)
Alaska	554	0	----	----	----	----	----	----	----
Arizona	39,720	174	(0.4)	131	9	34	(19.5)	140	(93.6)
Arkansas	1,442	14	(1.0)	11	2	1	(7.1)	13	(84.6)
California									
Los Angeles	26,306	216	(0.8)	13	12	191	(88.4)	25	(52.0)
San Francisco	12,630	48	(0.4)	34	14	0	(0.0)	48	(70.8)
California (excludes Los Angeles and San Francisco)	18,680	174	(0.9)	77	68	29	(16.7)	145	(53.1)
Colorado	1,668	8	(0.5)	5	3	0	(0.0)	8	(62.5)
Connecticut	45,282	70	(0.2)	63	7	0	(0.0)	70	(90.0)
Delaware	5,052	18	(0.4)	14	4	0	(0.0)	18	(77.8)
District of Columbia	12,149	94	(0.8)	27	51	16	(17.0)	78	(34.6)
Florida	128,307	1,101	(0.9)	731	83	287	(26.1)	814	(89.8)
Georgia	94,524	596	(0.6)	173	63	360	(60.4)	236	(73.3)
Hawaii	1,305	3	(0.2)	3	0	0	(0.0)	3	(100.0)
Idaho	5,286	5	(0.1)	2	3	0	(0.0)	5	(40.0)
Illinois									
Chicago	5,801	51	(0.9)	28	6	17	(33.3)	34	(82.4)
Illinois (excludes Chicago)	15,625	22	(0.1)	20	1	1	(4.5)	21	(95.2)
Indiana	11,916	17	(0.1)	6	10	1	(5.9)	16	(37.5)
Iowa	5,993	16	(0.3)	16	0	0	(0.0)	16	(100.0)
Kansas	12,688	38	(0.3)	34	4	0	(0.0)	38	(89.5)
Kentucky	10,890	26	(0.2)	22	1	3	(11.5)	23	(95.7)
Louisiana ^e	80,883	215	(0.3)	86	0	129	(60.0)	86	(100.0)
Maine	893	0	----	----	----	----	----	----	----
Maryland									
Baltimore	23,713	68	(0.3)	49	18	1	(1.5)	67	(73.1)
Maryland (excludes Baltimore)	15,433	28	(0.2)	16	12	0	(0.0)	28	(57.1)
Massachusetts	28,542	93	(0.3)	57	30	6	(6.5)	87	(65.5)
Michigan	21,458	90	(0.4)	71	19	0	(0.0)	90	(78.9)

CDC-funded jurisdiction	HIV tests			Interview for Partner Services					
	All HIV tests ^a	Newly diagnosed HIV-positive tests ^b	Newly diagnosed HIV positivity (%)	Interviewed	Not Interviewed	Missing/invalid	Missing /invalid (%)	Denominator for reported percentage ^c	Reported percentage ^d (%)
Minnesota	2,190	4	(0.2)	4	0	0	(0.0)	4	(100.0)
Mississippi	32,638	151	(0.5)	127	12	12	(7.9)	139	(91.4)
Missouri	34,035	66	(0.2)	53	3	10	(15.2)	56	(94.6)
Montana	1,208	0	----	----	----	----	----	----	----
Nebraska	5,093	8	(0.2)	7	0	1	(12.5)	7	(100.0)
Nevada	13,680	79	(0.6)	67	7	5	(6.3)	74	(90.5)
New Hampshire	466	4	(0.9)	4	0	0	(0.0)	4	(100.0)
New Jersey	26,895	119	(0.4)	64	22	33	(27.7)	86	(74.4)
New Mexico	5,275	25	(0.5)	23	2	0	(0.0)	25	(92.0)
New York									
New York City	34,618	231	(0.7)	125	79	27	(11.7)	204	(61.3)
New York (excludes New York City)	9,864	88	(0.9)	68	8	12	(13.6)	76	(89.5)
North Carolina	18,765	47	(0.3)	39	6	2	(4.3)	45	(86.7)
North Dakota	2,973	3	(0.1)	2	1	0	(0.0)	3	(66.7)
Ohio	7,205	134	(1.9)	112	18	4	(3.0)	130	(86.2)
Oklahoma	3,143	24	(0.8)	1	0	23	(95.8)	1	(100.0)
Oregon	5,578	25	(0.4)	23	2	0	(0.0)	25	(92.0)
Pennsylvania									
Pennsylvania (excludes Philadelphia)	45,631	119	(0.3)	102	17	0	(0.0)	119	(85.7)
Philadelphia	25,978	104	(0.4)	46	17	41	(39.4)	63	(73.0)
Rhode Island	1,196	2	(0.2)	2	0	0	(0.0)	2	(100.0)
South Carolina	36,018	185	(0.5)	94	39	52	(28.1)	133	(70.7)
South Dakota	411	0	----	----	----	----	----	----	----
Tennessee	61,427	354	(0.6)	25	9	320	(90.4)	34	(73.5)
Texas									
Houston	54,899	265	(0.5)	15	3	247	(93.2)	18	(83.3)
Texas (excludes Houston)	177,725	666	(0.4)	343	239	84	(12.6)	582	(58.9)
Utah	995	2	(0.2)	2	0	0	(0.0)	2	(100.0)
Vermont	42	2	(4.8)	2	0	0	(0.0)	2	(100.0)
Virginia	26,920	120	(0.4)	80	31	9	(7.5)	111	(72.1)
Washington	7,632	49	(0.6)	24	22	3	(6.1)	46	(52.2)
West Virginia	1,745	3	(0.2)	2	0	1	(33.3)	2	(100.0)

CDC-funded jurisdiction	HIV tests			Interview for Partner Services					
	All HIV tests ^a	Newly diagnosed HIV-positive tests ^b	Newly diagnosed HIV positivity (%)	Interviewed	Not Interviewed	Missing/invalid	Missing /invalid (%)	Denominator for reported percentage ^c	Reported percentage ^d (%)
Wisconsin	6,800	24	(0.4)	21	3	0	(0.0)	24	(87.5)
Wyoming	2,408	1	(0.0)	1	0	0	(0.0)	1	(100.0)
Puerto Rico	9,392	82	(0.9)	61	4	17	(20.7)	65	(93.8)
U.S. Virgin Islands	1,086	3	(0.3)	1	2	0	(0.0)	3	(33.3)
Total	1,338,665	6,458	(0.5)	3,420	1,031	2,007	(31.1)	4,451	(76.8)

Data Source: Centers for Disease Control and Prevention National HIV Prevention Program Monitoring and Evaluation (NHM&E) data reported through EvaluationWeb[®] as of September 15, 2021.

^a Includes only tests with negative or positive results; tests with discordant or inconclusive results are excluded.

^b A newly diagnosed HIV-positive test refers to a person who has a current HIV-positive test result (includes unconfirmed preliminary positive rapid tests and confirmed positive tests) and no indication of a previous HIV-positive test.

^c Number of persons with newly diagnosed HIV whose test records have valid and complete information on interview for Partner Services. This is the denominator used to calculate the reported percentage.

^d Reported percentage excludes tests without data to calculate the outcome (i.e., invalid, missing, or "Don't Know").

^e Experienced reporting challenges because of Hurricane Ida.

Table 6. CDC-funded HIV testing and linkage to HIV medical care among persons with previously diagnosed HIV infection not in HIV medical care, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2020

CDC-funded jurisdiction	HIV tests			Linkage to HIV Medical Care in 30 days ^d					
	All HIV tests ^a	Previously diagnosed HIV-positive tests ^b	Previously diagnosed HIV-positive tests not in care ^c	Linked	Not linked	Missing/invalid	Missing /invalid (%)	Denominator for reported percentage ^e	Reported percentage ^f (%)
Alabama	47,994	341	272	56	198	18	(6.6)	254	(22.0)
Alaska	554	2	1	1	0	0	(0.0)	1	(100.0)
Arizona	39,720	69	18	11	7	0	(0.0)	18	(61.1)
Arkansas	1,442	47	10	4	3	3	(30.0)	7	(57.1)
California									
Los Angeles	26,306	238	3	2	1	0	(0.0)	3	(66.7)
San Francisco	12,630	83	33	28	4	1	(3.0)	32	(87.5)
California (excludes Los Angeles and San Francisco)	18,680	110	51	45	4	2	(3.9)	49	(91.8)
Colorado	1,668	5	1	0	0	1	(100.0)	0	----
Connecticut	45,282	24	7	3	3	1	(14.3)	6	(50.0)
Delaware	5,052	10	7	6	1	0	(0.0)	7	(85.7)
District of Columbia	12,149	79	6	3	2	1	(16.7)	5	(60.0)
Florida	128,307	838	20	17	0	3	(15.0)	17	(100.0)
Georgia	94,524	247	170	100	35	35	(20.6)	135	(74.1)
Hawaii	1,305	1	0	----	----	----	----	----	----
Idaho	5,286	0	0	----	----	----	----	----	----
Illinois									
Chicago	5,801	63	9	3	1	5	(55.6)	4	(75.0)
Illinois (excludes Chicago)	15,625	21	4	2	2	0	(0.0)	4	(50.0)
Indiana	11,916	2	0	----	----	----	----	----	----
Iowa	5,993	1	0	----	----	----	----	----	----
Kansas	12,688	2	1	1	0	0	(0.0)	1	(100.0)
Kentucky	10,890	18	2	0	0	2	(100.0)	0	----
Louisiana ^g	80,883	653	4	3	1	0	(0.0)	4	(75.0)
Maine	893	1	0	----	----	----	----	----	----
Maryland									
Baltimore	23,713	174	29	7	13	9	(31.0)	20	(35.0)

CDC-funded jurisdiction	HIV tests			Linkage to HIV Medical Care in 30 days ^d					
	All HIV tests ^a	Previously diagnosed HIV-positive tests ^b	Previously diagnosed HIV-positive tests not in care ^c	Linked	Not linked	Missing/invalid	Missing /invalid (%)	Denominator for reported percentage ^e	Reported percentage ^f (%)
Maryland (excludes Baltimore)	15,433	36	10	4	1	5	(50.0)	5	(80.0)
Massachusetts	28,542	333	163	82	77	4	(2.5)	159	(51.6)
Michigan	21,458	61	45	35	6	4	(8.9)	41	(85.4)
Minnesota	2,190	11	1	0	0	1	(100.0)	0	----
Mississippi	32,638	48	8	4	3	1	(12.5)	7	(57.1)
Missouri	34,035	87	31	13	15	3	(9.7)	28	(46.4)
Montana	1,208	0	0	----	----	----	----	----	----
Nebraska	5,093	6	0	----	----	----	----	----	----
Nevada	13,680	71	18	12	4	2	(11.1)	16	(75.0)
New Hampshire	466	0	0	----	----	----	----	----	----
New Jersey	26,895	143	40	37	3	0	(0.0)	40	(92.5)
New Mexico	5,275	4	0	----	----	----	----	----	----
New York									
New York City	34,618	213	127	105	8	14	(11.0)	113	(92.9)
New York (excludes New York City)	9,864	161	31	22	9	0	(0.0)	31	(71.0)
North Carolina	18,765	104	35	11	22	2	(5.7)	33	(33.3)
North Dakota	2,973	0	0	----	----	----	----	----	----
Ohio	7,205	36	26	22	3	1	(3.8)	25	(88.0)
Oklahoma	3,143	4	4	2	1	1	(25.0)	3	(66.7)
Oregon	5,578	9	4	1	2	1	(25.0)	3	(33.3)
Pennsylvania									
Pennsylvania (excludes Philadelphia)	45,631	272	128	30	98	0	(0.0)	128	(23.4)
Philadelphia	25,978	152	77	41	36	0	(0.0)	77	(53.2)
Rhode Island	1,196	0	0	----	----	----	----	----	----
South Carolina	36,018	62	32	22	9	1	(3.1)	31	(71.0)
South Dakota	411	0	0	----	----	----	----	----	----
Tennessee	61,427	84	16	10	4	2	(12.5)	14	(71.4)
Texas									
Houston	54,899	461	198	42	16	140	(70.7)	58	(72.4)

CDC-funded jurisdiction	HIV tests			Linkage to HIV Medical Care in 30 days ^d					
	All HIV tests ^a	Previously diagnosed HIV-positive tests ^b	Previously diagnosed HIV-positive tests not in care ^c	Linked	Not linked	Missing/invalid	Missing /invalid (%)	Denominator for reported percentage ^e	Reported percentage ^f (%)
Texas (excludes Houston)	177,725	899	114	64	50	0	(0.0)	114	(56.1)
Utah	995	1	0	----	----	----	----	----	----
Vermont	42	0	0	----	----	----	----	----	----
Virginia	26,920	82	13	5	8	0	(0.0)	13	(38.5)
Washington	7,632	6	0	----	----	----	----	----	----
West Virginia	1,745	0	0	----	----	----	----	----	----
Wisconsin	6,800	11	2	2	0	0	(0.0)	2	(100.0)
Wyoming	2,408	0	0	----	----	----	----	----	----
Puerto Rico	9,392	63	26	19	5	2	(7.7)	24	(79.2)
U.S. Virgin Islands	1,086	6	1	1	0	0	(0.0)	1	(100.0)
Total	1,338,665	6,455	1,798	878	655	265	(14.7)	1,533	(57.3)

Data Source: Centers for Disease Control and Prevention National HIV Prevention Program Monitoring and Evaluation (NHM&E) data reported through EvaluationWeb[®] as of September 15, 2021.

^a Includes only tests with negative or positive results; tests with discordant or inconclusive results are excluded.

^b A previously diagnosed HIV-positive test is a test on a client who was previously reported to the HIV surveillance system or who reports a previous positive HIV test or evidence of a previous positive test is found on review of other data sources.

^c Excludes persons already in HIV medical care.

^d A person is considered linked to HIV medical care within 30 days if they have attended an appointment for HIV medical care within 30 days of the current test.

^e Number of persons with previously diagnosed HIV whose test records have valid and complete information on attendance and date of first appointment for HIV medical care within 30 days. This is the denominator used to calculate the reported percentage.

^f Reported percentage excludes tests without data to calculate the outcome (i.e., invalid, missing, or "Don't Know").

^g Experienced reporting challenges because of Hurricane Ida.